Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from seven to eight members with Matthew Pauls appointed as a Class I director through the 2027 annual meeting.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from seven to eight members with Matthew Pauls appointed as a Class I director through the 2027 annual meeting
- Independent director brings public biopharma leadership, commercialization, clinical development, and rare-disease experience
- Equity incentive: option for 6,000 common shares vesting monthly over 36 months, subject to continued service
- Annual board and committee retainers payable under the company’s non-employee director compensation policy
- No related-party transactions or selection arrangements disclosed; Nasdaq independence determination supports governance compliance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.